Immuno Oncology Talks

In our tenth episode of the “Immuno Oncology Talks”,  we will discuss oncogenes in relation to immune responses with our guest, Professor Juha Klefström, from the Finnish Cancer Institute at the University of Helsinki, Finland. Professor Klefström is an expert in breast cancer biology and immuno-oncology, leading a research group focusing on oncogenes like Myc, in relation to the immune system and the tumour immune micro environment. 

For more information please visit :
Sanofi Immuno Oncology Talks website


MAT-BE-2400162 (ver.1 ) 02 2024 

In our ninth episode of the “Immuno Oncology Talks”, we will discuss the rapidly evolving field of the microbiome in cancer immunotherapy with our guest, Professor Jeroen Raes, from the Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium. Professor Raes has established a world leading lab, where they combine large-scale, next-generation sequencing with novel computational approaches to investigate the function and variability of the healthy human microbiome, and to study and compare this with alterations identified in various diseases.

For more information please visit :
Sanofi Immuno Oncology Talks website 

MAT-BE-2300657 (ver. 1.0) June 2023

In our eight episode of the “Immuno Oncology Talks”, we will hear about the current challenges of getting cancer cell and gene therapies on the market from a health economic perspective. Our guest, Professor Cornelis Boersma, from University Medical Center Groningen and Open University, in the Netherlands, has an extensive experience within health economics and health care policy. Apart from his previous experience within the pharma industry, he is actively involved as a scientist, consultant and entrepreneur in various national and international initiatives, organizations, networks, and projects in the field of healthcare.

For more information please visit :
Sanofi Immuno Oncology Talks website 

MAT-BE-2300504 (ver 1) 05 2023

This episode, the seventh of our “Immuno Oncology Talks”, will be covering “Therapeutic RNA vaccines in cancer immunotherapy”, with our two guests, Professor Karine Breckpot and Professor Kris Thielemans, from the Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, in Belgium. Both experts have a long background within innovative immunotherapy strategies in cancer, and especially within mRNA vaccination. Professor Thielemans and his team has developed the mRNA based TriMix technology, and initiated several clinical trials in this field.

 For more information please visit :

Sanofi Immuno Oncology Talks website 

MAT-BE-2300298 04 2023

In our sixth episode of “Immuno Oncology Talks”, we will discuss non-viral RNA treatment approaches in cancer immunotherapy with our guest, professor Karine Breckpot from the Laboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, in Belgium. Professor Breckpot has a strong background within innovative immunotherapy strategies in cancer, and especially with mRNA technologies as a way to target the immune system.

For more information please visit :
Sanofi Immuno Oncology Talks website

MAT-BE-2300154 (ver.1.0) 02 2023

In the current, and fifth episode of the “Immuno Oncology Talks”, we discuss adoptive therapy with engineered T cell receptors, with Professor Reno Debets from the Erasmus MC Cancer Institute in the Netherlands. Professor Debets research aims to explore therapeutic strategies by developing and testing adoptive T cell therapy and understand and intervene with the cross-talk between tumor cells and T cells.

For more information please visit:
Sanofi Immuno Oncology Talks website

MAT-BE-2300064 (Ver 1.0) Jan 2023

The fourth episode of “Immuno Oncology Talks”, Professor Marjolein van Egmond from the Amsterdam University Medical Center, in the Netherlands, will shed light on neutrophils as effector cells in cancer therapy. Professor Marjolein van Egmond specializes in the innate immune system and is focusing on elucidating the therapeutic potential of neutrophils in cancer, with a specific interest in IgA and bispecific antibodies to activate the neutrophils. 

For more information please visit:
Sanofi Immuno Oncology Talks website

MAT-BE-2200978 (ver. 1.0) 12 2022

In the third episode of the “Immuno Oncology Talks”, we have had the pleasure to discuss tumor infiltrating lymphocytes for adoptive cell therapy with Professor Inge Marie Svane from the National Center for Cancer Immune Therapy in Denmark. Professor Inge Marie Svane has built up this centre into a leading European translational research centre. Apart from her vast expertise is T-cell based adoptive cell therapy, her research also focuses on other cellular therapies, cancer vaccines, and immune regulation.

For more information please visit:
Sanofi Immuno Oncology Talks website

MAT-BE-2200834 (ver. 1.0) 11 2022

In our second episode of the “Immuno Oncology Talks”, Associate Professor Evren Alici, from the Karolinska Institutet in Sweden, was invited to discuss NK cell-based cancer immunotherapies, accompanied by his colleague Professor Hans-Gustaf Ljunggren. The primary focus of Professor Alici´s research is on novel NK cell-based therapies, and includes generation and testing of genetically engineered NK cells, like chimeric receptor and CAR-NK cells. Associate Professor Alici is also co-director of the NextGenNK Competence Center (https://ki.se/en/research/nextgennk).

For more information please visit:
Sanofi Immuno Oncology Talks website

MAT-BE-2200747 (ver 1.0) 09 2022

The first episode in the “Immuno Oncology Talks” is about the biology of Natural Killer (NK) cells. The interview is conducted with Professor Hans-Gustaf Ljunggren at Karolinska Institutet in Sweden together with his colleague Associate professor Evren Alici. Professor Ljunggren, who has been studying NK cells for more than 30 years, is director of the NextGenNK Competence Center (https://ki.se/en/research/nextgennk), coordinated by Karolinska Institutet, which has the mission to facilitate development of NK cell-based cancer immunotherapies.

For more information please visit:
Sanofi Immuno Oncology Talks website

MAT-BE-2200746 (ver 1.0) 09 2022